EUCTR2020-001708-41-IT进行中（未招募）1 期
Enoxaparin for thromboprophylaxis in hospitalized COVID-19 patients: comparison of 40 mg o.d. versus 40 mg b.i.d. A randomized Clinical Trial - X-COVID 19
AZIENDA OSPEDALIERA AO OSPEDALE NIGUARDA CA' GRANDA0 个研究点目标入组 2,712 人开始时间: 2020年6月24日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 2,712
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •All-comers patients aged >=18 years and admitted to hospital with laboratory-confirmed SARS-CoV-2 infection.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 2000
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 700
排除标准
- •Patients admitted directly to an intensive care unit;
- •Estimated creatinine clearance <15 ml/min/1.73m2;
- •Patients needing anticoagulant for prior indication;
- •Patients treated with heparin at any increased dose compared to prophylactic regimen before enrolment;
- •Patients at high bleeding risk or experiencing clinically significant bleeding;
- •Patients involved in competitive clinical trials exploring antithrombotic treatments;
- •Any other significant disease or disorder which, in the opinion of the investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant’s ability to participate in the trial
研究者
相似试验
已完成
3 期
Comparison of Two Doses of Enoxaparin for Thromboprophylaxis in Hospitalized COVID-19 PatientsCovid19NCT04366960Niguarda Hospital189
进行中（未招募）
1 期
Exoxaparin in hospitalized patients with moderate-severe COVID19Hospitalized adult patients with microbiologically confirmed moderate-severe COVID-19 infectionMedDRA version: 20.0Level: SOCClassification code 10021881Term: Infections and infestationsSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.0Level: SOCClassification code 10038738Term: Respiratory, thoracic and mediastinal disordersSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2020-001308-40-ITALMA MATER STUDIORUM UNIVERSITà DI BOLOGNA100
已完成
1 期
Comparison of two drug thinning agents (unfractionated heparin and low-molecular weight heparin) for prevention of stroke after brain aneurysm treatment utilizing coils or stentsIntracranial AneurysmACTRN12616001277437Royal Brisbane and Women's Hospital154
进行中（未招募）
1 期
The OVID study will show whether prophylactic-dose enoxaparin improves survival and reduces any hospitalizations in ambulatory patients aged 50 or older diagnosed with COVID-19, a novel viral disease characterized by severe systemic, pulmonary, and vessel inflammation and coagulation activatioPatients diagnosed with COVID-19, a novel viral disease characterized by severe systemic, pulmonary, and vessel inflammation and coagulation activation.MedDRA version: 20.0Level: SOCClassification code 10021881Term: Infections and infestationsSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 22.1Level: LLTClassification code 10061229Term: Lung infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2020-005624-10-DEniversity Hospital Zurich1,000
已完成
不适用
Enoxaparin versus control for venous thromboembolic prophylaxis after total knee arthroplasty in Asian patients: a randomized controlled trialosteoarthritis of kneeknee arthroplastyDVT prophylaxisTCTR20140527001Golden Jubilee Medical Center50